共同藥業(300966.SZ):與新華製藥共設同新藥業 以投建年產300噸醋酸阿奈可他和200噸17α-羥基黃體酮項目
格隆匯 4 月 13日丨共同藥業(300966.SZ)公佈,為延伸激素系列產品產業鏈,增強市場競爭優勢,結合公司實際及發展規劃,公司與新華製藥(000756.SZ)於2021年4月13日在淄博簽署出資人協議,協議規定雙方共同出資設立山東同新藥業有限公司(暫定名,“同新藥業”或“合資公司”),並投資建設年產300噸醋酸阿奈可他和200噸17α-羥基黃體酮項目。
同新藥業註冊資金12000萬元,其中共同藥業以現金出資人民幣4800萬元,持股比例40%;新華製藥以現金出資人民幣7200萬元,持股比例60%。
與新華製藥共同出資設立合資公司,有利於合作雙方加強戰略協同性,形成利益共同體;合資公司設立後,將投資建設年產300噸醋酸阿奈可他和200噸17α-羥基黃體酮項目。投建項目實施將延伸公司產業鏈,完善產品佈局,進一步強化規模優勢,提高盈利能力。合資公司在未來實際運營管理過程中,可能受到下游醫藥行業政策變化、行業集中度提升導致競爭加劇、項目產能不達預期等諸多風險,公司將通過密切關注國家政策環境調整,適度分散客户集中風險,積極進行技術創新、降低成本等措施,有效防範及應對上述風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.